HISTORY REPEATS ITSELF, SIX MONTHS LATER
GSK’s phase III cancer vaccine miss in NSCLC is double trouble for Agenus
By Marie Powers
Thursday, March 20, 2014
History repeated itself for Agenus Inc. six months after Glaxosmithkline plc’s (GSK) phase III DERMA trial of its MAGE-A3 cancer immunotherapeutic, formulated with Agenus’ QS-21 Stimulon adjuvant, missed its primary endpoint of extending disease-free survival (DFS) in melanoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.